Status:
COMPLETED
A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis
Lead Sponsor:
Centocor, Inc.
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of the study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with plaque-type psoriasis.
Detailed Description
The purpose of this study is to investigate the safety and possible usefulness of infliximab therapy for patients with severe plaque psoriasis. In a previous small study of infliximab in 33 patients w...
Eligibility Criteria
Inclusion
- Must be 18 years of age or older at time of enrollment
- may be male or female
- Have had a diagnosis of plaque-type psoriasis at least 6 months prior to screening
- Have plaque-type psoriasis covering at least 10% of total BSA at baseline
- Have previously received PUVA and/or other systemic treatment for psoriasis
Exclusion
- Have non-plaque forms of psoriasis
- Have a history of drug-induced psoriasis
- Are pregnant, nursing, or planning pregnancy within 12 months of enrollment
- Have had any previous treatment with infliximab or any therapeutic agent
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2003
Estimated Enrollment :
249 Patients enrolled
Trial Details
Trial ID
NCT00230529
End Date
January 1 2003
Last Update
June 9 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.